Get the app Watchlists Portfolios Alerts Sign in Get started

Menu

Market-Moving News for February 23rd

Benzinga Newsdesk Feb 23, 2026 8 months ago

MoversTrading Ideas

VNDA: 54% | On Friday, The FDA Approved Vanda Pharmaceuticals' Bysanti (Milsaperidone) Tablets, A First Line Therapy For The Acute Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder And

VNDA: 54% | On Friday, The FDA Approved Vanda Pharmaceuticals' Bysanti (Milsaperidone) Tablets, A First Line Therapy For The Acute Treatment Of Manic Or Mixed Episodes Associated With Bipolar I Disorder And For Schizophrenia In Adults

NVO: -15% | Novo Nordisk's Headline Results From REDEFINE 4 Phase 3 Trial Of Cagrisema Shows 23% Weight Loss After 84 Weeks Of Treatment, Also Cagrisema 2.4/2.4 mg Did Not Meet The Primary Endpoint Of Showing Non-inferiority On Weight Loss Compared To Tirzepatide 15 mg At 84 Weeks

IPW: -16% | IPW stock has given up its prior gain. iPower shares were trading higher. The company reported Q2 financial results.

Read the original